TITLE

Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder

AUTHOR(S)
Matson, Johnny L.; Sipes, Megan; Fodstad, Jill C.; Fitzgerald, Mary E.
PUB. DATE
July 2011
SOURCE
CNS Drugs;2011, Vol. 25 Issue 7, p597
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Autism spectrum disorder (ASD) is a particularly important risk factor for challenging behaviours such as aggression, tantrums, self-injury and pica. Adults with ASD have rarely been studied with respect to these problems. This is particularly disconcerting since there are far more adults than children with ASD. In addition, because of adults' increased physical size and longer history of these problems, treating these behaviours effectively is important. Psychological methods, particularly applied behaviour analysis, and pharmacotherapy have been the most frequently addressed treatments for challenging behaviours associated with ASD in the research literature. In many cases, challenging behaviours have clear environmental antecedents. In these cases, behavioural interventions, such as applied behaviour analysis, should be used to reduce the behaviours. When environmental factors cannot be identified or when challenging behaviours are very severe, pharmacological treatments may be necessary in combination with behavioural interventions. Newer antipsychotics are the most researched medications for use with this population. Currently, risperidone and aripiprazole are the only medications that have US FDA approval for the treatment of behaviours associated with ASD, specifically irritability; however, they are indicated for use in children not adults. It is important not to use medications unnecessarily, due to possible side effects associated with their use. Based on available research, some recommendations for the treatment of challenging behaviours of adults (and children) with ASD include the use of functional assessment, side-effect monitoring of medications and behavioural methods whenever possible. Additionally, future research in this area needs to focus more on adults, as most current research has used child samples.
ACCESSION #
78388097

 

Related Articles

  • ROLE OF ARIPIPRAZOLE IN THE MANAGEMENT OF IRRITABILITY IN AUTISTIC SPECTRUM DISORDER. Helal, Muhammad Nabeel; Mushtaq, Imran // Journal of Pakistan Psychiatric Society;2011, Vol. 8 Issue 2, p97 

    The article focuses on the findings of a study which examines the role of aripiprazole in the treatment of irritability in children with autistic spectrum disorder (ASD). It is inferred that aripiprazole is an atypical antipsychotic which impacts the dopaminergic and serotonergic...

  • Risperidone for irritability associated with autism.  // WHO Drug Information;2006, Vol. 20 Issue 4, p271 

    The article reports that risperidone orally disintegrating tablets have been approved by the U.S. Food and Drug Administration. The drug is an adult antipsychotic for the treatment of irritability in autistic children and adolescents. It is the first one to get the approval to treat behaviors...

  • Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders. Scahill, Lawrence; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Handen, Benjamin; Johnson, Cynthia; Dziura, James; Butter, Eric; Sukhodolsky, Denis; Swiezy, Naomi; Mulick, James; Stigler, Kimberly; Bearss, Karen; Ritz, Louise; Wagner, Ann; Vitiello, Benedetto // Journal of Autism & Developmental Disorders;May2009, Vol. 39 Issue 5, p720 

    This paper presents the rationale for a 24-week, randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of noncompliance, irritability and adaptive functioning. In this model, medication reduces tantrums, aggression...

  • Visual factors in autistic spectrum disorder. Ludlow, Amanda // Optometry Today;11/15/2013, Vol. 53 Issue 22, p46 

    The article focuses on visual problems that are most prevalent in patients with autism spectrum disorder (ASD) and highlights key characteristics that should be considered when performing visual assessments of ASD patients. It states that optometric problems in children with ASD have implicated...

  • Product Profiles: Autism Spectrum Disorders - Growing Interest in Underserved Market.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that a report on the product profile for the treatment of autism spectrum disorders (ASDs) has been added to the offering of Research and Markets. It mentions that Abilify has been newly introduced in the market after getting approved by the U.S. Food and Drug Administration....

  • Autism spectrum disorders. Nightingale, Sarah // Nature Reviews Drug Discovery;Oct2012, Vol. 11 Issue 10, p745 

    The article focuses on autism spectrum disorders (ASDs), a developmental disorder with four core symptoms such as communication deficits, irritability and restricted interests. It mentions that are were only two approved pharmacotherapies which can be used in managing ASDs, the risperidone...

  • In this issue.  // Nature Reviews Drug Discovery;Oct2013, Vol. 12 Issue 10, p721 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the draft guidance document issued by the U.S. Food and Drug Administration, development of enhanced epilepsy therapies, and pathophysiology of autism spectrum disorder (ASD).

  • Alkermes' drug passes trial. Investor's Business Daily // Investors Business Daily;4/ 9/2014, pA02 

    The biotech said its schizophrenia drug hit its phase three trial goals. It will file for FDA approval in Q3.

  • The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. May, Meghan; Beauchemin, Megan; Vary, Calvin; Barlow, Deborah; Houseknecht, Karen L. // PLoS ONE;6/26/2019, Vol. 14 Issue 6, p1 

    Atypical antipsychotic medications such as risperidone are widely prescribed for diverse psychiatric indications including schizophrenia, bipolar disorder and depression. These medications have complex pharmacology and are associated with significant endocrine and metabolic side effects. This...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics